Who are Epirubicin, Paclitaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Doxorubicine + docetaxel sequential.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epirubicin-paclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Epirubicin, Paclitaxel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epirubicin, Paclitaxel (Epirubicin, Paclitaxel) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (anthracycline + taxane). Area: Oncology.

phase 3 Chemotherapy combination (anthracycline + taxane) Topoisomerase II (epirubicin); β-tubulin/microtubules (paclitaxel) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Epirubicin, Paclitaxel (Epirubicin, Paclitaxel) — Chinese Academy of Medical Sciences. Epirubicin and paclitaxel are chemotherapy agents that work together to inhibit cancer cell division and induce apoptosis through different mechanisms.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Epirubicin, Paclitaxel TARGET	Epirubicin, Paclitaxel	Chinese Academy of Medical Sciences	phase 3	Chemotherapy combination (anthracycline + taxane)	Topoisomerase II (epirubicin); β-tubulin/microtubules (paclitaxel)
Doxorubicine + docetaxel sequential	Doxorubicine + docetaxel sequential	Sanofi	phase 3	Chemotherapy combination (anthracycline + taxane)	Topoisomerase II (doxorubicin); β-tubulin/microtubules (docetaxel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (anthracycline + taxane) class)

Chinese Academy of Medical Sciences · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epirubicin, Paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/epirubicin-paclitaxel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab